Via News Knowledge File

Sanofi

organization80% conf.·synced Aug 19, 2026

Pharmaceutical company partnered with Teva for duvakitug additional indications

sourced metrics

805

relationships

stated objectives

Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Market Cap

54837636507USD

Aug 18, 2026reference only

Stock Return Ytd

-6.8%

Aug 18, 2026reference only

Stock Price

44.97USD

Aug 18, 2026reference only

Price 52 Week Low

41.33USD

Aug 18, 2026reference only

Price 52 Week High

52.34USD

Aug 18, 2026reference only

Margin

-68.7percent

Apr 1, 2026source

Eps

4.97USD

Mar 3, 2026⚠ sources conflictsource

Rare Disease Experience

40years

Feb 2, 2026source

Rare Disease Commitment

40years

Feb 2, 2026source

Collaboration Revenue

5.9billion_USD

Jan 30, 2026⚠ sources conflictsource

Cash

877000000.0USD

Dec 31, 2025reference only

Total Assets

126805000000.0USD

Dec 31, 2025reference only

Gross Profit

33667000000.0USD

Dec 31, 2025reference only

Rd Expense

7842000000.0USD

Dec 31, 2025reference only

Shares Outstanding

1219427096.0shares

Dec 31, 2025reference only

Acquisition Price Per Share

15.50USD

Dec 24, 2025source

China Approvals 2025

5approvals

Dec 11, 2025source

China Drug Approvals 2025

5approvals

Dec 11, 2025source

Stated objectives

Advance Dynavax's shingles vaccine candidate (Z-1018) through clinical development

source

stated

Augment Sanofi's presence in adult immunization by combining Dynavax's vaccines with Sanofi's global scale, development capabilities and commercial reach

source

stated

Provide vaccine protection across the lifespan through differentiated vaccine portfolio

source

stated

Submit global regulatory submissions for amlitelimab

source

stated

Report results from AQUA and ESTUARY phase 3 studies

source

stated

Study dupilumab in chronic pruritus of unknown origin, lichen simplex chronicus, and allergic fungal rhinosinusitis in phase 3 studies

source

stated

Complete global regulatory submissions for amlitelimab

source

stated

Publish results from AQUA and ESTUARY phase 3 studies

source

stated

Present COAST 1, COAST 2, SHORE and ATLANTIS results at upcoming medical conferences

source

stated

Study dupilumab in phase 3 trials for chronic pruritus of unknown origin, chronic lichen simplex, and allergic fungal rhinosinusitis

source

stated

Relationship graph · 805 connections

Employs

237

Developed by

141

regulates

Competes with

headquartered in

regulated by

researched at

Owns

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →